09.01.05
Europharma, Green Bay, WI, has secured the North American rights to Kinospherine, a fat blocker. This patented complex of ingredients has been clinically shown to help prevent the absorption of dietary fats in the body, while maintaining healthy digestion. According to the company, Kinospherine blocks 21 grams of fat per day and is three and a half times more effective than chitosan. It has a high lipid absorption capacity, which prevents lipase action by blocking the fatty acids.
In other developments, Europharma has entered into a joint venture with VitaPlant, a Swiss research institute that studies phytomedicinal products. Europharma is currently funding six new research projects with VitaPlant in the development of new plant-based medicines. These new phytomedicinal products will be commercially available worldwide in 12 to 18 months.
In other developments, Europharma has entered into a joint venture with VitaPlant, a Swiss research institute that studies phytomedicinal products. Europharma is currently funding six new research projects with VitaPlant in the development of new plant-based medicines. These new phytomedicinal products will be commercially available worldwide in 12 to 18 months.